Quest Diagnostics Inc (DGX)

04:23 AM

Quest Diagnostics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan

04:23 AM

08:01 AM

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.

08:01 AM

Mar 31, 2025

Quest Health Review 2025: Services, Pricing, and Reliability - Healthline

Mar 31, 2025

Mar 31, 2025

JPMorgan Chase & Co. Raises Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat

Mar 31, 2025

Mar 29, 2025

Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN

Mar 29, 2025

Mar 28, 2025

SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow

Mar 28, 2025

Mar 27, 2025

Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN

Mar 27, 2025

Mar 27, 2025

Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com

Mar 27, 2025

Mar 26, 2025

Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart

Mar 26, 2025

Mar 26, 2025

Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 23, 2025

Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey

Mar 23, 2025

Mar 21, 2025

DGX Stock Set to Benefit From New Google Cloud Partnership - MSN

Mar 21, 2025

Mar 20, 2025

Top 8 AI News Updates Investors Shouldn’t Miss - Insider Monkey

Mar 20, 2025

Mar 20, 2025

What 9 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga

Mar 20, 2025

Mar 20, 2025

Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance - AlphaStreet

Mar 20, 2025

Mar 20, 2025

Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating - Marketscreener.com

Mar 20, 2025

Mar 20, 2025

Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance

Mar 20, 2025

Mar 19, 2025

Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock - Investing.com

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock By Investing.com - Investing.com Canada

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics falls on Q1 outlook headwinds, reaffirms FY guidance - MSN

Mar 19, 2025

Mar 19, 2025

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - TradingView

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics (DGX) Unveils Strategic Plans at Investor Day - GuruFocus.com

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics stock falls on Q1 headwinds (DGX:NYSE) - Seeking Alpha

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day - Quantisnow

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics projects steady growth beyond 2025 - Investing.com India

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics Lowers Q1 Outlook, Reaffirms 2025 Guidance -March 19, 2025 at 08:42 am EDT - Marketscreener.com

Mar 19, 2025

Mar 19, 2025

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day – Company AnnouncementFT.com - Financial Times

Mar 19, 2025

Mar 18, 2025

Quest Diagnostics (NYSE:DGX) Leverages Google Cloud AI For Enhanced Patient Experience - Simply Wall St

Mar 18, 2025

Mar 18, 2025

Quest Diagnostics Revolutionizes Lab Testing With Google Cloud AI Partnership - StockTitan

Mar 18, 2025

Mar 17, 2025

Baird Adjusts Price Target on Quest Diagnostics to $190 From $189, Maintains Outperform Rating - Marketscreener.com

Mar 17, 2025

Mar 16, 2025

Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 - GuruFocus.com

Mar 16, 2025

Mar 14, 2025

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX) - Barchart

Mar 14, 2025

Mar 14, 2025

Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Mar 14, 2025

Mar 11, 2025

SBI Securities Co. Ltd. Takes Position in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World

Mar 11, 2025

Mar 10, 2025

Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance

Mar 10, 2025

Mar 09, 2025

Catherine T. Doherty Sells 5,370 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock - Defense World

Mar 09, 2025

Mar 08, 2025

Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock By Investing.com - Investing.com Australia

Mar 08, 2025

Mar 08, 2025

Mutual of America Capital Management LLC Decreases Stake in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World

Mar 08, 2025

Mar 07, 2025

Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock - Investing.com India

Mar 07, 2025

Mar 07, 2025

Quest Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Citigroup Downgrades Quest Diagnostics (NYSE:DGX) to Neutral - Defense World

Mar 06, 2025

Mar 05, 2025

Quest Diagnostics EVP sells $125,865 in stock - Investing.com

Mar 05, 2025

Mar 05, 2025

Quest Diagnostics EVP sells $125,865 in stock By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 05, 2025

SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 2,871 shares and was granted 4,434 shares, increasing direct ownership by 14% to 13,119 units (SEC Form 4) - Quantisnow

Mar 05, 2025

Mar 05, 2025

Labcorp Gains Citi Upgrade While Quest Diagnostics Faces Downgrade On Margin Concerns — Retail Sentiment Mixed - MSN

Mar 05, 2025

Mar 04, 2025

Quest Diagnostics Incorporated : Your health comes first -March 04, 2025 at 10:54 pm EST - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

The Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts - Benzinga

Mar 04, 2025

Mar 04, 2025

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 04, 2025

Mar 04, 2025

Citigroup Downgrades Quest Diagnostics to Neutral From Buy, Price Target is $185 -March 04, 2025 at 05:37 am EST - Marketscreener.com

Mar 04, 2025